Carter Todd Alfred 4

What Happened Carter Todd Alfred, Chief Scientific Officer of Voyager Therapeutics (VYGR), received equity awards on February 6, 2026: 33,000 restricted stock units (RSUs) and a stock option covering 154,000 shares. Both grants were reported on a Form 4 filed February 10, 2026. The reported acquisition price for both items is $0.00, indicating these were compensation awards rather than open-market purchases.

Key Details

• Transaction date: February 6, 2026; Form 4 filed February 10, 2026 (appears timely).
• Awards reported:
  • 33,000 RSUs (F1) — acquisition code A; reported price $0.00.
  • Option covering 154,000 shares (derivative grant, code A) — reported price $0.00.
• Vesting:
  • RSUs vest over 3 years: 1/3 on the one-year anniversary, then 1/3 each year thereafter, subject to continued service (F1).
  • Option vests over 4 years: 1/48th vests after one month and monthly thereafter, subject to continued service (F2).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No cash was paid for the awards; fair value or exercise price for the option (if any) is not reported here.
• No indication in the filing of a 10b5-1 plan, tax-withholding sale, or late filing code.

Context These entries are grants of compensation (RSUs and an option grant), not purchases or sales. Such awards are common for executive compensation and do not by themselves indicate the insider is buying or selling shares in the market. The option is a derivative grant (not an exercise); any future value to the insider depends on vesting and, for the option, its exercise price and Voyager's future stock price.